Literature DB >> 16755237

Pneumocystis carinii pneumonia in patients with connective tissue disease.

Jian Li1, Xiao-Ming Huang, Wei-Gang Fang, Xue-Jun Zeng.   

Abstract

BACKGROUND: Although the association of Pneumocystis carinii pneumonia (PCP) with connective tissue disease (CTD) has been noted for a long time, there are few series reported.
OBJECTIVE: The objective of this study was to describe clinical features and prognosis of PCP infections in patients with CTD in China.
METHODS: We retrospectively reviewed the characteristics, clinical features, and prognosis of PCP in patients with CTD in a single hospital.
RESULTS: A total of 7 cases were reviewed (systemic lupus erythematosus n = 2, microscopic polyangiitis n = 2, dermatomyositis n = 2, polymyositis n = 1). Eighty-six percent of patients developed PCP within 3 months of the diagnosis of CTD. All patients were receiving daily glucocorticoid therapy and cytotoxic drugs before the diagnosis of PCP. Most patients had fever, progressive dyspnea, and dry cough at onset of PCP. The mean duration of symptoms before PCP diagnosis was 7 days. Absolute lymphocyte counts ranged from 126 to 528/microL. The CD4 lymphocyte counts of all patients were 87 +/- 78/microL. One patient was diagnosed by induced sputum; 6 patients were diagnosed by bronchoalveolar lavage fluid. Complicating fungal infection was found in 4 of 7 patients at the time of diagnosis of PCP. All patients were treated by trimethoprim-sulfamethoxazole and corticosteroids. Six (86%) patients died. The mean duration of the time from diagnosis to death was 14 +/- 4 days.
CONCLUSIONS: Our results suggest that PCP is an uncommon and fatal opportunistic infection in patients with CTD. When patients with CTD who are receiving immunosuppressive therapy have low lymphocyte counts and/or CD4 lymphocyte counts less than 250/microL develop fever, dry cough, dyspnea, and chest radiography shows diffuse interstitial infiltrate, the diagnosis of PCP should be highly suspected. Induced sputum or BAL must be quickly performed to confirm diagnosis. Further study is needed as to whether earlier treatment will improve prognoses or whether patients with CTD with low CD4 counts should receive PCP prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755237     DOI: 10.1097/01.rhu.0000221794.24431.36

Source DB:  PubMed          Journal:  J Clin Rheumatol        ISSN: 1076-1608            Impact factor:   3.517


  9 in total

Review 1.  Pneumocystis Pneumonia and the Rheumatologist: Which Patients Are At Risk and How Can PCP Be Prevented?

Authors:  Rachel M Wolfe; James E Peacock
Journal:  Curr Rheumatol Rep       Date:  2017-06       Impact factor: 4.592

2.  Factors Associated with Pneumocystis jirovecii Pneumonia in Patients with Rheumatoid Arthritis Receiving Methotrexate: A Single-center Retrospective Study.

Authors:  Shin-Ichiro Ohmura; Yoichiro Homma; Takayuki Masui; Toshiaki Miyamoto
Journal:  Intern Med       Date:  2021-09-11       Impact factor: 1.282

3.  Red fist and muscle weakness with a rare complication.

Authors:  Iris van Groeningen; Joyce Arnoldus; Roos Perenboom; Alexandre Voskuyl
Journal:  BMJ Case Rep       Date:  2014-02-20

4.  Risk factors of Pneumocystis jeroveci pneumonia in patients with systemic lupus erythematosus.

Authors:  Ratchaya Lertnawapan; Kitti Totemchokchyakarn; Kanokrat Nantiruj; Suchela Janwityanujit
Journal:  Rheumatol Int       Date:  2008-09-25       Impact factor: 2.631

Review 5.  Diagnosis and management of infectious complications of childhood rheumatic diseases.

Authors:  Rhina D Castillo; Wendy De la Pena; Katherine A B Marzan
Journal:  Curr Rheumatol Rep       Date:  2013-04       Impact factor: 4.592

6.  Pneumocystis jirovecii pneumonia in mycophenolate mofetil-treated patients with connective tissue disease: analysis of 17 cases.

Authors:  Yongfeng Zhang; Yi Zheng
Journal:  Rheumatol Int       Date:  2014-06-20       Impact factor: 2.631

7.  Pneumocystis Pneumonia in Patients with Autoimmune Diseases: A Retrospective Study Focused on Clinical Characteristics and Prognostic Factors Related to Death.

Authors:  Minjiang Chen; Xinlun Tian; Fang Qin; Jiong Zhou; Jinjing Liu; Mengzhao Wang; Kai-Feng Xu
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

8.  Pneumocystis jirovecii pneumonia in autoimmune rheumatic diseases: a nationwide population-based study.

Authors:  Jin-Hua Chen; Chi-Ching Chang; Hui-Ching Hsu; Yu-Sheng Chang; Tsung-Yun Hou; Lung-Fang Chen; Li-Fang Hu; Tzu-Min Lin; Chi-Sheng Chiou; Kai-Len Tsai; Sheng-Hong Lin; Pei-I Kuo; Wei-Sheng Chen; Yi-Chun Lin
Journal:  Clin Rheumatol       Date:  2021-03-01       Impact factor: 2.980

9.  Comparison of trimethoprim-sulfamethoxazole and aerosolized pentamidine for primary prophylaxis of Pneumocystis jiroveci pneumonia in immunocompromised patients with connective tissue disease.

Authors:  Miho Kimura; Sumiaki Tanaka; Akira Ishikawa; Hirahito Endo; Shunsei Hirohata; Hirobumi Kondo
Journal:  Rheumatol Int       Date:  2007-12-14       Impact factor: 3.580

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.